Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Temelimab after Rituximab in Relapsing Multiple Sclerosis (RMS)
2019-004822-15Phase 2Completed
- Sponsor
- GeNeuro
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of temelimab in multiple sclerosis (MS) (4 arms), sponsored by GeNeuro. Primary endpoint: Overall summary of adverse events. Started Jan 2020; status: completed.
02
Drugs
temelimab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2019-004822-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004822-15.